Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. STKE, 6 November 2007
Vol. 2007, Issue 411, p. pe60
[DOI: 10.1126/stke.4112007pe60]

PERSPECTIVES

Neurotrophic Factors and Parkinson’s Disease: The Emergence of a New Player?

William Dauer*

Departments of Neurology and Pharmacology, Columbia University, Neurological Institute of New York, Box 204, 710 West 168th Street, New York, NY 10032, USA.

Abstract: The administration of neurotrophic factors is a potential approach to the therapy of neurodegenerative disorders such as Parkinson’s disease. However, issues relating to compound delivery and potential side effects have limited the clinical application of this treatment strategy. The identification of CDNF and MANF, which constitute a new class of neurotrophic factors active against dopaminergic neurons, may provide new hope for therapeutic approaches to neurodegenerative disorders based on neurotrophic factors or downstream components of their signaling pathways.

Contact information. *E-mail, wtd3{at}columbia.edu

Citation: W. Dauer, Neurotrophic Factors and Parkinson’s Disease: The Emergence of a New Player? Sci. STKE 2007, pe60 (2007).

Read the Full Text



To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882